Share

Bausch & Lomb has patented a method for creating a water extractable ophthalmic device with specific properties. The device is made from a unique polymerization product and has high water content, low contact angle, and high oxygen permeability. GlobalData’s report on Bausch & Lomb gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Bausch & Lomb Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bausch & Lomb, was a key innovation area identified from patents. Bausch & Lomb's grant share as of February 2024 was 59%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11897985B2) discloses a method for preparing a water extractable ophthalmic device. The method involves curing a monomeric mixture in a mold, comprising cyclic lactams, organosilicon-containing monomers, bulky siloxane monomers, and a crosslinking agent mixture. The ophthalmic device, upon dry releasing from the mold, exhibits specific properties such as an equilibrium water content of at least 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least 60 Barrers. Additionally, the device may have a water extractable content of less than about 15 wt. %, providing enhanced performance characteristics.

The composition of the monomeric mixture, including the percentages of cyclic lactams, organosilicon-containing monomers, bulky siloxane monomers, and crosslinking agents, plays a crucial role in determining the properties of the water extractable ophthalmic device. The method allows for customization of the device for specific applications, such as contact lenses or hydrogels, with variations in equilibrium water content, contact angle, and oxygen permeability. Furthermore, the inclusion of additional components like 2-hydroxyethyl methacrylate (HEMA) and ultraviolet (UV) blockers further enhances the performance and functionality of the ophthalmic device. The curing process, whether thermal or infrared, ensures the formation of a high-quality product with desirable characteristics, making it a significant innovation in the field of ophthalmic devices.

To know more about GlobalData’s detailed insights on Bausch & Lomb, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.